Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04134325
Title Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.